On 22 June 2026, Masimo, a Danaher company, received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory ...
Medical Device Network on MSN
Masimo secures FDA approval for OIRD detection on wearable patient monitor
The newly cleared capability uses AI through the smartSET pulse oximetry sensor platform.
Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
CEO Rainer Blair said Danaher has the money and “leadership bandwidth” to strike further deals across any of its three business areas.
These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which ...
Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results